Goldman Sachs’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-4,000
| Closed | -$12K | – | 6575 |
|
|
2017
Q4 | $12K | Sell |
4,000
-60,000
| -94% | -$218K | ﹤0.01% | 6184 |
|
|
2017
Q3 | $287K | Buy |
64,000
+21,300
| +50% | +$94.6K | ﹤0.01% | 5505 |
|
|
2017
Q2 | $196K | Buy |
42,700
+16,800
| +65% | +$67.5K | ﹤0.01% | 5811 |
|
|
2017
Q1 | $109K | Sell |
25,900
-200
| -0.8% | -$830 | ﹤0.01% | 6030 |
|
|
2016
Q4 | $108K | Buy |
26,100
+10,700
| +69% | +$56.9K | ﹤0.01% | 6104 |
|
|
2016
Q3 | $125K | Buy |
15,400
+6,900
| +81% | +$58.7K | ﹤0.01% | 6118 |
|
|
2016
Q2 | $66K | Sell |
8,500
-1,500
| -15% | -$12.9K | ﹤0.01% | 6315 |
|
|
2016
Q1 | $77K | Sell |
10,000
-27,100
| -73% | -$198K | ﹤0.01% | 6213 |
|
|
2015
Q4 | $400K | Sell |
37,100
-6,700
| -15% | -$60.9K | ﹤0.01% | 5105 |
|
|
2015
Q3 | $303K | Sell |
43,800
-13,500
| -24% | -$110K | ﹤0.01% | 5599 |
|
|
2015
Q2 | $508K | Buy |
57,300
+21,600
| +61% | +$204K | ﹤0.01% | 5200 |
|
|
2015
Q1 | $352K | Sell |
35,700
-806,600
| -96% | -$10.1M | ﹤0.01% | 5492 |
|
|
2014
Q4 | $10.3M | Buy |
842,300
+792,300
| +1,585% | +$9.68M | ﹤0.01% | 2323 |
|
|
2014
Q3 | $499K | Buy |
+50,000
| New | +$464K | ﹤0.01% | 5266 |
|
|
2014
Q1 | – | Sell |
-102,300
| Closed | -$340K | – | 7005 |
|
|
2013
Q4 | $340K | Sell |
102,300
-54,800
| -35% | -$159K | ﹤0.01% | 5596 |
|
|
2013
Q3 | $474K | Buy |
+157,100
| New | +$1.08M | ﹤0.01% | 5195 |
|
Goldman Sachs's ACHN Position: Q1 2020 in Review
Goldman Sachs sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 3,048,297 shares — an estimated $18.4M sold.
Goldman Sachs first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $64.5M in Q4 2014. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Goldman Sachs reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Goldman Sachs sold 3,048,297 Achillion Pharmaceuticals shares in Q1 2020, an estimated $18.4M.
- Goldman Sachs first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Goldman Sachs's Achillion Pharmaceuticals position peaked at $64.5M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Goldman Sachs's 13F filing for Q1 2020, filed 15 May 2020.